Tags : Launches


Roche Launches New Configurations for Cobas Pro to Increase Testing

Shots: Roche launches eight new configurations for Cobas pro integrated solutions in countries accepting the CE mark and is designed to address the individual needs to maximize throughput and efficiency Cobas pro integrated solutions can deliver up to 4,400 tests/ hr., doubling its previous testing capacity. The addition of the new configurations allows labs to […]Read More


Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop

Shots: The new peptide MAM workflow for the BioAccord LC-MS system that helps to monitor critical quality attributes of protein-based drugs that can affect the safety & efficacy of innovator drugs and biosimilars By integrating BioAccord system on the waters_connect platform, scientists have a sensitive multiplexed method to accurately assess the attributes of protein-based drugs […]Read More

COVID-19 MedTech

Abbott Launches Pandemic Defense Coalition to Detect Future Threats

Shots: The coalition builds on Abbott’s excellence in virus surveillance and aid in analyzing virus samples for unknown diseases and detects mutations and variants including COVID-19 The goal of the Pandemic Defense Coalition is to identify new pathogens, analyze potential risk level, assess public health impact in real-time, and contain outbreaks when new virus threats […]Read More


Abbott Launches NeuroSphere Virtual Clinic for Remote Neurostim Programming in

Shots: The US FDA has approved NeuroSphere Virtual Clinic that allows a patient to communicate with a physician and remotely receive stimulation settings in real-time regardless of location NeuroSphere Virtual Clinic allows clinicians to provide new treatment settings remotely to the patient’s neurostimulation device using the clinician programmer app The virtual clinic is compatible with […]Read More


Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory

Shots: Health Canada has authorized Idacio on Oct 30, 2020, for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Health Canada’s approval was based on analytical, pre/ clinical data that demonstrated similar PK, efficacy, safety and immunogenicity to the Humira. Idacio […]Read More


Viatris Launches Hulio (biosimilar, adalimumab) in Canada

Shots: Health Canada has approved Hulio, a biosimilar referencing AbbVie’s Humira (adalimumab), which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab indications The approval was based on an analytical, pre/ clinical program. Fujifilm Kyowa Kirin conducted a P-III ARABESC study that demonstrated no differences in terms […]Read More